David A. Dodd has been named president, chief executive officer and chairman at BioReliance Corp. From 2000 through 2006, Mr. Dodd served as president and chief executive officer of Serologicals Corp., a publicly traded company that was sold to Millipore Corporation in 2006 for $1.4 billion. From 1995 to 2000, he was pPresident and chief executive officer of Solvay Pharmaceuticals, a subsidiary of the Solvay Group. Mr. Dodd entered the pharmaceutical industry in 1977 with Abbott Laboratories and...